US FDA Hears Competing Messages On Off-Label Communications
Over the course of a two-day meeting at FDA headquarters, the agency heard from the medtech industry, which argued for expanding rights to off-label promotion, and consumer groups that worry about the possible impact on the public health. The meeting is intended to inform FDA's comprehensive review of its regulations and policies governing firms' communications about unapproved uses of approved/cleared products.
You may also be interested in...
Pre-Trump agency memo on manufacturer communications about unapproved uses says new court rulings and studies on off-label uses and adverse reactions support restrictions; whether agency’s new leadership has the same view remains to be seen.
Two draft guidance documents would allow a broader range of communications with payers and others about information not included on device labeling, or concerning products without FDA approval.
Definitive guidance from FDA on off-label communications may be some time away and is likely to focus on physicians and payers before consumer-focused messaging, according to attorney from Arnall Golden Gregory.